Jenny C Chang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2821520/publications.pdf

Version: 2024-02-01

128 papers	14,374 citations	36271 51 h-index	30058 103 g-index
132 all docs	132 docs citations	132 times ranked	19749 citing authors

#	Article	IF	Citations
1	Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. Journal of the National Cancer Institute, 2008, 100, 672-679.	3.0	1,632
2	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13820-13825.	3.3	1,257
3	Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 1688-1698.	3.2	990
4	Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts. Stem Cell Reports, 2014, 2, 78-91.	2.3	854
5	Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, The, 2003, 362, 362-369.	6.3	804
6	Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet, The, 1998, 352, 98-101.	6.3	678
7	XBP1 promotes triple-negative breast cancer by controlling the HIF1Î± pathway. Nature, 2014, 508, 103-107.	13.7	663
8	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. Cancer Research, 2013, 73, 4885-4897.	0.4	394
9	Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs. Cancer Cell, 2007, 11, 498-512.	7.7	351
10	Cancer stem cells. Medicine (United States), 2016, 95, S20-S25.	0.4	303
11	Microenvironmental Regulation of Epithelialâ€“Mesenchymal Transitions in Cancer. Cancer Research, 2012, 72, 4883-4889.	0.4	265
12	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 2013, 31, 1726-1731.	0.8	238
13	Survival of patients with metastatic breast carcinoma. Cancer, 2003, 97, 545-553.	2.0	237
14	Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Locally Advanced Breast Cancers. Journal of Clinical Oncology, 2011, 29, 166-173.	0.8	235
15	Epithelial-Mesenchymal Transition (EMT) in Tumor-Initiating Cells and Its Clinical Implications in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2010, 15, 253-260.	1.0	229
16	Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research, 2013, 19, 1512-1524.	3.2	224
17	Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Research, 2012, 14, 202.	2.2	204
18	Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients. Journal of Clinical Oncology, 2005, 23, 1169-1177.	0.8	189

#	Article	IF	Citations
19	Microfluidics separation reveals the stem-cellâ€“like deformability of tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18707-18712.	3.3	186
20	Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Research, 2015, 17, 25.	2.2	175
21	Thermal Enhancement with Optically Activated Gold Nanoshells Sensitizes Breast Cancer Stem Cells to Radiation Therapy. Science Translational Medicine, 2010, 2, 55ra79.	5.8	167
22	Patients with Breast Cancer: Differences in Color Doppler Flow and Gray-Scale US Features of Benign and Malignant Axillary Lymph Nodes. Radiology, 2000, 215, 568-573.	3.6	161
23	Optimism, social support and psychosocial functioning among women with breast cancer. Psycho-Oncology, 2006, 15, 595-603.	1.0	156
24	Molecular characterization of breast cancer CTCs associated with brain metastasis. Nature Communications, 2017, 8, 196.	5.8	148
25	Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment, 2008, 108, 233-240.	1.1	123
26	A targetable LIFRâ^'NF-Î¹Bâ^'LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333.	5.8	117
27	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical Cancer Research, 2017, 23, 4035-4045.	3.2	104
28	Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8838-8843.	3.3	99
29	The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Letters, 2016, 376, 249-258.	3.2	99
30	Self-Forgiveness, Spirituality, and Psychological Adjustment in Women with Breast Cancer. Journal of Behavioral Medicine, 2006, 29, 29-36.	1.1	97
31	Chloroquine Eliminates Cancer Stem Cells Through Deregulation of Jak2 and DNMT1. Stem Cells, 2014, 32, 2309-2323.	1.4	95
32	Neoadjuvant Trastuzumab and Docetaxel in Patients With Breast Cancer: Preliminary Results. Clinical Breast Cancer, 2003, 4, 348-353.	1.1	92
33	Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic. JCO Oncology Practice, 2021, 17, e36-e43.	1.4	91
34	Identification of Novel Kinase Targets for the Treatment of Estrogen Receptorâ€“Negative Breast Cancer. Clinical Cancer Research, 2009, 15, 6327-6340.	3.2	89
35	A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Research, 2020, 22, 121.	2.2	89
36	Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Research and Treatment, 2006, 95, 229-233.	1.1	88

#	Article	IF	Citations
37	A Novel Method of Transcriptional Response Analysis to Facilitate Drug Repositioning for Cancer Therapy. Cancer Research, 2012, 72, 33-44.	0.4	85
38	Benign and Malignant Breast Masses and Axillary Nodes: Evaluation with Echo-enhanced Color Power Doppler US. Radiology, 2001, 220, 795-802.	3.6	83
39	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clinical Cancer Research, 2015, 21, 3995-4003.	3.2	82
40	Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Breast Cancer Research, 2018, 20, 108.	2.2	81
41	Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Research, 2013, 15, 201.	2.2	80
42	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research, 2016, 76, 1942-1953.	0.4	77
43	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Research and Treatment, 2018, 167, 731-740.	1.1	71
44	Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 1152-1162.	3.2	62
45	Therapeutic targeting of casein kinase 1Î´ in breast cancer. Science Translational Medicine, 2015, 7, 318ra202.	5.8	61
46	Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research, 2013, 15, R77.	2.2	60
47	Studying Cancer Stem Cell Dynamics on PDMS Surfaces for Microfluidics Device Design. Scientific Reports, 2013, 3, 2332.	1.6	59
48	Attribution of Blame, Self-forgiving Attitude and Psychological Adjustment in Women with Breast Cancer. Journal of Behavioral Medicine, 2007, 30, 351-357.	1.1	58
49	A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Research, 2020, 22, 4.	2.2	58
50	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metabolism, 2021, 33, 78-93.e7.	7.2	57
51	Decreased TGFÎ² signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Research and Treatment, 2010, 119, 305-314.	1.1	56
52	Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model. PLoS ONE, 2012, 7, e30207.	1.1	56
53	Role of RPL39 in Metaplastic Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw292.	3.0	55
54	Ductal lavage and the clinical management of women at high risk for breast carcinoma. Cancer, 2002, 94, 292-298.	2.0	51

#	Article	IF	Citations
55	Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells. Breast Cancer Research, 2016, 18, 6.	2.2	49
56	Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles. ACS Nano, 2021, 15, 6326-6339.	7.3	49
57	A gene transcription signature of obesity in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 993-1000.	1.1	48
58	Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. Journal of Biological Chemistry, 2016, 291, 23756-23768.	1.6	48
59	A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Science Translational Medicine, 2021, 13, eabj5070.	5.8	48
60	Novel Modeling of Cancer Cell Signaling Pathways Enables Systematic Drug Repositioning for Distinct Breast Cancer Metastases. Cancer Research, 2013, 73, 6149-6163.	0.4	44
61	Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*. Molecular and Cellular Proteomics, 2015, 14, 1959-1976.	2.5	44
62	Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition. Oncotarget, 2015, 6, 25320-25338.	0.8	43
63	HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports, 2018, 10, 212-227.	2.3	42
64	Activating Transcription Factor 4 Modulates TGFÎ²-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clinical Cancer Research, 2018, 24, 5697-5709.	3.2	42
65	Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/Î²-catenin and TGFÎ² signaling pathways. European Journal of Nutrition, 2019, 58, 3207-3219.	1.8	42
66	HER2 Inhibition: From Discovery to Clinical Practice: Fig. 1.. Clinical Cancer Research, 2007, 13, 1-3.	3.2	38
67	The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Research and Treatment, 2012, 131, 425-436.	1.1	38
68	Prognostic Markers for Invasive Micropapillary Carcinoma of the Breast: A Population-Based Analysis. Clinical Breast Cancer, 2013, 13, 133-139.	1.1	38
69	SNX27â€“retromer assembly recycles MT1-MMP to invadopodia and promotes breast cancer metastasis. Journal of Cell Biology, 2020, 219, .	2.3	38
70	Self-blame, Self-forgiveness, and Spirituality in Breast Cancer Survivors in a Public Sector Setting. Journal of Cancer Education, 2010, 25, 343-348.	0.6	35
71	NO and COX2: Dual targeting for aggressive cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13591-13593.	3.3	34
72	A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Research and Treatment, 2021, 190, 265-275.	1.1	34

#	Article	IF	Citations
73	A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL) Tj ETQq1 1 0.784314 rgBT /Over	2.4	33
74	Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Research and Treatment, 2005, 94, 279-284.	1.1	30
75	Cancer therapeutic targeting using mutantâ€“p53-specific siRNAs. Oncogene, 2019, 38, 3415-3427.	2.6	29
76	Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Research, 2013, 15, 205.	2.2	27
77	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment, 2016, 158, 441-454.	1.1	26
78	Clinical management of women with genomic BRCA1 and BRCA2 mutations*. Breast Cancer Research and Treatment, 2001, 69, 101-113.	1.1	25
79	The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Research, 2005, 7, 100-4.	2.2	25
80	Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research, 2014, 24, 542-559.	5.7	23
81	A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer. Clinical Breast Cancer, 2021, 21, 199-204.	1.1	23
82	A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes. JCO Clinical Cancer Informatics, 2018, 2, 1-11.	1.0	21
83	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers, 2022, 14, 1760.	1.7	20
84	The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast. Breast Journal, 2019, 25, 1171-1176.	0.4	19
85	Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Communications, 2019, 39, 1-9.	3.7	19
86	Non-surgical aspects of ovarian cancer. Lancet, The, 1994, 343, 335-340.	6.3	17
87	Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093615.	1.4	17
88	Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Scientific Reports, 2021, 11, 82.	1.6	16
89	Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Breast Cancer Research and Treatment, 2019, 178, 251-261.	1.1	15
90	The ERÎ²4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERÎ² variants ERÎ²2 and ERÎ²5 increase aggressiveness of TNBC by regulation of hypoxic signaling. Oncotarget, 2018, 9, 12201-12211.	0.8	15

#	Article	IF	Citations
91	Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. Npj Breast Cancer, 2022, 8, 30.	2.3	14
92	Reversible and Irreversible Cardiac Dysfunction Associated with Trastuzumab in Breast Cancer. Breast Cancer Research and Treatment, 2002, 74, 131-134.	1.1	11
93	Dual HER2 blockade: preclinical and clinical data. Breast Cancer Research, 2014, 16, 419.	2.2	11
94	Deep learning analytics for diagnostic support of breast cancer disease management. , 2017, , .		10
95	Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Research, 2020, 22, 48.	2.2	10
96	Enhanced Mammary Progesterone Receptor-A Isoform Activity in the Promotion of Mammary Tumor Progression by Dietary Soy in Rats. Nutrition and Cancer, 2010, 62, 774-782.	0.9	8
97	Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: AÂPopulation-based Study. Clinical Breast Cancer, 2018, 18, e97-e105.	1.1	8
98	Eniluracil Plus 5-Fluorouracil and Leucovorin: Treatment for Metastatic Breast Cancer Patients in Whom Capecitabine Treatment Rapidly Failed. Clinical Breast Cancer, 2014, 14, 26-30.	1.1	6
99	Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Research and Treatment, 2020, 181, 623-633.	1.1	6
100	The role of combined radiation and immunotherapy in breast cancer treatment. Journal of Radiation Oncology, 2015, 4, 347-354.	0.7	5
101	Pharmacogenetics of Breast Cancer: Toward the Individualization of Therapy. Cancer Investigation, 2009, 27, 699-703.	0.6	3
102	Abstract 16: Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. , 2010, , .		1
103	Abstract 3015: Annexin A3 is selectively expressed in MET-like as compared to EMT-like breast cancer stem cells. , 2014, , .		1
104	Abstract 2586: The natural compound hydroxytyrosol inhibits the Wnt/EMT axis and migration of triple-negative breast cancer cells.. , 2013, , .		1
105	Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases. Breast Cancer Research and Treatment, 2022, 193, 613-623.	1.1	1
106	Utility of microarrays in the management of breast cancer patients. Drug Discovery Today: Therapeutic Strategies, 2005, 2, 307-311.	0.5	0
107	Reply to M. Russillo et al. Journal of Clinical Oncology, 2011, 29, 2835-2835.	0.8	0
108	Breast Cancer Stem Cells. , 2016, , 133-151.		0

#	Article	IF	Citations
109	Pharmacology, biology and clinical use of triphenylethylenes. , 2002, , 33-44.		0
110	Endocrine prevention of breast cancer. , 2005, , 30-34.		0
111	Abstract 4370: Network-based signatures for drug repositioning and combination for the breast tumor initiating cells. , 2011, , .		0
112	Abstract 1664: Maternal embryonic leucine aipper kinase (MELK) is a critical regulator of proliferation and is independently prognostic in estrogen receptor-negative breast cancer. , 2011, , .		0
113	Abstract LB-110: Bioinformatic discovery of repositioned drugs to target breast tumor initiating cells. , 2011, , .		0
114	Abstract 231: Upregulation of HER3 (ErbB3) levels and function counteracts the antitumor effect of HER2 and PI3K inhibitors. , 2011, , .		0
115	Abstract LB-106: Expression of stem cell biomarkers in benign breast tissue from patients with triple negative breast cancer. , 2011, , .		0
116	Abstract 2853: Discovery of phosphatases that regulate growth and tumorigenicity of ER-negative breast cancers. , 2012, , .		0
117	Abstract 4862: Autocrine secreted IL-6 and IL-8 play critical and non-redundant roles in basal-like breast cancer cell transformation and growthin vitroandin vivo. , 2012, , .		0
118	Abstract 2857: Induced expression of DUSP4 and PPM1A in ER-negative breast cancer cells suppresses proliferation and invasion. , 2012, , .		0
119	Primary systemic therapy in breast cancer. , 2013, , 489-504.		0
120	Abstract A91: Developing novel treatment strategies for triple-negative breast cancer metastasis. , 2013, , .		0
121	Abstract 856: High expression of DUSP4 in ER-negative breast cancer cells suppresses growth and invasion.. , 2013, , .		0
122	Abstract 3909: Assessing the role of tumor vascularity in nanotherapeutics delivery.. , 2013, , .		0
123	Abstract 2712: Identification of tumor initiating genes RPL39 and MLF2 that mediate lung metastasis through nitric oxide signaling and mesenchymal to epithelial transition.. , 2013, , .		0
124	Abstract 1996: Identification of four subgroups of Triple Negative Breast Cancer (TNBC) by genomic profiling.. , 2013, , .		0
125	Abstract 237: Chloroquine inhibits cancer stem cells in triple negative breast cancer via regulation of DNA methylation.. , 2013, , .		0
126	Abstract 5279: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing cell cycle. , 2014, , .		0

#	Article	IF	Citations
127	Abstract 4024: iNOS inhibition increases survival in triple negative breast cancer by targeting metastasis and epithelial-mesenchymal transition. , 2014, , .		0
128	SERMs and Breast Cancer Prevention. , 0, , 267-278.		0